Baricitinib
| Evidence Level: L5 | Predicted Indications: 2 |
Table of Contents
- Baricitinib
- Baricitinib: From Immune-Mediated Inflammatory Conditions to Colobomatous Microphthalmia-Rhizomelic Dysplasia Syndrome
Baricitinib: From Immune-Mediated Inflammatory Conditions to Colobomatous Microphthalmia-Rhizomelic Dysplasia Syndrome
One-Sentence Summary
Baricitinib is an oral JAK1/JAK2 inhibitor marketed in the US as Olumiant, used in immune-mediated inflammatory conditions. The TxGNN model predicts it may be effective for colobomatous microphthalmia-rhizomelic dysplasia syndrome, a rare congenital developmental disorder. There are currently 0 clinical trials and 0 publications supporting this direction, so the prediction rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Predicted New Indication | Colobomatous microphthalmia-rhizomelic dysplasia syndrome |
| TxGNN Prediction Score | 99.94% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 4 license records (3 share NDA207924; 1 has no listed number) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the input. Baricitinib is a JAK1/JAK2 inhibitor, and its known use is in immune-mediated inflammatory conditions. The input lists no original indications, so that context comes from the drug class rather than from label text.
No established mechanistic link connects JAK-STAT inhibition to this syndrome. The syndrome causes ocular and skeletal malformations from disrupted development, and it has no known JAK-STAT-driven pathology. Structural congenital defects are also unlikely to be reversed by an immunomodulator in adults.
The very high score (99.94%) cannot be traced to a biological rationale. It may reflect knowledge-graph topology, such as shared gene or phenotype neighbours, rather than a true therapeutic signal. It needs independent validation, for example pathway-level or gene-level analysis, before any clinical interpretation.
A second prediction, brachydactyly-syndactyly syndrome (score 99.94%, also L5), shows the same pattern. It is a congenital limb malformation with no evidence linking it to JAK1/JAK2 inhibition, and no trials or literature exist.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| NDA207924 | Olumiant | Film-coated tablet (oral) | Eli Lilly and Company |
| No number listed | Baricitinib | Film-coated tablet (oral) | Eli Lilly and Company |
The NDA207924 entry appears three times in the source data. It is shown once here. No approved indication text was provided for any record.
Safety Considerations
Please refer to the package insert for safety information. No drug interaction records were found for this drug.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has the highest score tier but no trials, no literature, and no plausible mechanism. The syndrome is a congenital structural disorder with no known inflammatory driver, so the score looks like a knowledge-graph artefact rather than a real signal.
To proceed, the following is needed:
- Mechanism of action data (MOA) for baricitinib
- Package insert warnings and contraindications, which block safety screening
- Pathway- or gene-level analysis testing whether JAK-STAT signalling is involved in this syndrome
- Any preclinical or case-level evidence supporting the link
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.